Abediterol
http://dbpedia.org/resource/Abediterol an entity of type: Thing
Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials. It acts as a dual β2 adrenergic agonist and muscarinic antagonist and is classified as an ultra-long-acting β2 agonist (ultra-LABA). Its coformulation with mometasone furoate is also in Phase II clinical trials.
rdf:langString
rdf:langString
Abediterol
xsd:integer
34975653
xsd:integer
1053728949
rdf:langString
None
xsd:integer
25
xsd:integer
915133
xsd:integer
142077
xsd:integer
3039530
xsd:integer
10136846
<second>
87480.0
xsd:integer
2
xsd:integer
30
xsd:integer
5
rdf:langString
D10219
xsd:integer
2
xsd:integer
4
xsd:integer
11962616
rdf:langString
Inhalation
rdf:langString
FCCOCCCCCCNC[C@H]c3cccc2c3\C=C/CN2
xsd:integer
1
rdf:langString
SFYAXIFVXBKRPK-QFIPXVFZSA-N
rdf:langString
QXA167CM6F
rdf:langString
changed
xsd:integer
225
rdf:langString
Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials. It acts as a dual β2 adrenergic agonist and muscarinic antagonist and is classified as an ultra-long-acting β2 agonist (ultra-LABA). Its coformulation with mometasone furoate is also in Phase II clinical trials.
xsd:nonNegativeInteger
5163
xsd:string
915133-65-2
xsd:string
142077
xsd:string
3039530
xsd:string
QXA167CM6F
xsd:string
D10219
xsd:string
11962616